“Long-Term Safety and Efficacy of Tralokinumab in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years”. SKIN The Journal of Cutaneous Medicine, vol. 9, no. 2, Mar. 2025, p. s573, https://doi.org/10.25251/skin.10.supp.573.